Michael Amoroso - 02 Nov 2025 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
President and CEO, Director
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso
Issuer symbol
DTIL
Transactions as of
02 Nov 2025
Net transactions value
-$22,124
Form type
4
Filing time
04 Nov 2025, 16:15:28 UTC
Previous filing
04 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Amoroso Michael President and CEO, Director C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM /s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso 04 Nov 2025 0001830874

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise $0 +9,444 +8.6% $0.000000 118,984 02 Nov 2025 Direct F1, F2
transaction DTIL Common Stock Sale $22,124 -3,409 -2.9% $6.49 115,575 03 Nov 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -9,444 -100% $0.000000 0 03 Nov 2025 Common Stock 9,444 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.